Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de Efetividade e Segurança do Tisagenlecleucel em Pacientes Brasileiros com Leucemia Linfoblástica Aguda ou Linfoma Difuso de Grandes Células B

9 de novembro de 2026 atualizado por: Novartis Pharmaceuticals

Eficácia e segurança da terapia com tisagenlecleucel em pacientes brasileiros com leucemia linfoblástica aguda ou linfoma difuso de grandes células B: um estudo de registro prospectivo de 15 anos em duas coortes

This will be a multicenter, national, non-interventional, prospective cohort study

Visão geral do estudo

Descrição detalhada

Eligible participants will be pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary. It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years divided among the study indications.

Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a "Pre-infusion" and a "Post infusion follow-up period" for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first.

For the study, "pre-infusion" and "follow-up post infusion" phases are defined as:

  • "Pre-infusion" will consist of the patient's information from the time of diagnosis untiljust prior to infusion with tisagenlecleucel.
  • "Follow-up Post infusion" information will comprise any information from the infusionof tisagenlecleucel onwards.

Tipo de estudo

Observacional

Inscrição (Estimado)

200

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Novartis Pharmaceuticals

Locais de estudo

      • São Paulo, Brasil, 01509-010
        • Recrutamento
        • Novartis Investigative Site
      • São Paulo, Brasil, 01409-902
        • Recrutamento
        • Novartis Investigative Site
    • Belo Horizonte
      • Minas Gerais, Belo Horizonte, Brasil, 34006-059
        • Recrutamento
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasil, 41253-190
        • Recrutamento
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasil, 81520-060
        • Recrutamento
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasil, 01323-900
        • Recrutamento
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasil, 04544-000
        • Recrutamento
        • Novartis Investigative Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

1 segundo a 100 anos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

The study population will include pediatric/ adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia aged 0-25 years and adult patients aged ≥ 18 years with relapsed/refractory Diffuse Large B-cell Lymphoma and relapsed/refractory follicular lymphoma, who received tisagenlecleucel infusion in the commercial setting or out-of-specification.

Descrição

Inclusion Criteria:

Patients eligible for inclusion in this study must meet the following criteria:

  1. Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND

  2. Signed informed consent must be obtained prior to participation in study, AND

    For ALL participants:

  3. Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

  4. Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

    For DBLCL and FL participants:

  5. Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.

Exclusion Criteria:

  1. Patients who did not consent to data collection.
  2. Patients who received tisagenlecleucel infusion as part of any interventional clinical trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: OTHER

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
Acute Lymphoblastic Leukemia (ALL)

Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Diffuse Large B-cell Lymphoma (DLBCL)

Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Follicular Lymphoma (FL)

Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion.

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Overall response rate (ORR)
Prazo: Up to 15 years

The overall response rate will be defined as the total proportion of participants exhibiting either the best overall response (BOR) of complete or partial responses and the proportion of patient with BOR of CR/PR or CR/CRi for ALL patients will be reported along with its 95% CI.

For ALL participants, the BOR will be defined as a CR or a CRi in accordance with National Comprehensive Cancer Network (NCCN) guidelines and previous guidelines (Appelbaum et al 2007)(Cheson et al 2003).

For lymphomas, the BOR will be defined as a CR or PR in accordance with the Cheson response criteria (Cheson et al 2007) and the Lugano classification (Cheson et al 2016).

Up to 15 years
MRD negative overall response rate
Prazo: Up to 15 years

The percentage of B-cell ALL patients who achieve a Best Overall Response (BOR) of CR or CRi with a Minimal residual disease (MRD) negative bone marrow will be provided with 95% CI.

Up to 15 years
Duration of overall response (DOR)
Prazo: Up to 15 years

Duration of overall response (DOR) applies only to patients whose best overall disease response was either:

  • CR or PR for patients with lymphomas, or
  • CR or a CRi for patients with ALL.

DOR will be defined as the time from the date of first documented disease response (Complete Response (CR) or PR for patients with lymphomas, and Complete Remission (CR) or CRi for patients with ALL), whichever occurs first, to the date of first documented progression or first documented relapse according to indication, or to the date of death due to the underlying disease.

In case a patient does not have progression/relapse or death due to underlying disease (defined as the event for this outcome) prior to data cut-off, DOR will be censored at the date of the last assessment on or prior to the earliest censoring event.

Up to 15 years
Relapse-free survival (RFS)
Prazo: Up to 15 years

RFS is measured by the time from date of first documented disease response as CR or CRi to relapse or death due to any cause in ALL patients.

In case a patient does not have relapse or death due to any cause prior to data cutoff, RFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Event-free survival (EFS) for ALL patients
Prazo: Up to 15 years

EFS is the time from date of first tisagenlecleucel infusion to treatment failure, relapse or death from any cause, whichever occurred first, for B-cell ALL patients.

Up to 15 years
Progression free survival (PFS) for DLBCL patients
Prazo: Up to 15 years

PFS is defined as the time from the date of first infusion to the date of event defined as the first documented progression of lymphoma or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of the last adequate assessment.

In case a patient does not have progression or death prior to data cutoff, PFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Overall survival (OS)
Prazo: Up to 15 years

Overall survival is the time from date of first tisagenlecleucel infusion to the date of death due to any reason, In case a patient is alive at the date of last contact on or before data cutoff, OS is censored at the date of last contact.

Up to 15 years
Number of ALL patients with hematologic recovery
Prazo: Up to 15 years

Dates of hematological recovery (i.e., dates of Absolute Neutrophil Count (ANC) and platelet recovery) will be collected.

ANC recovery is defined as an ANC of ≥ 0.5 × 109/L (500/mm^3) for 3 consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of 3 consecutive laboratory values where the ANC is ≥ 0.5 × 109/L (CIBMTR).

The first date of the 3 consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 109/L should be recorded. It should be ensured that no platelet transfusions were administered for 7 days immediately preceding this date (CIBMTR).

Up to 15 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
The type and frequency of SAEs and AE of special interest
Prazo: Up to 15 years

The type and frequency of SAEs and AE of special interest (including secondary malignancies) will be collected

Up to 15 years
Incidence and severity of CRS and ICANS among HTLV 1 and 2 positive versus HTLV 1 and 2 negative patients
Prazo: Up to 15 years

Incidence and severity of Cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) among Human T-cell Lymphotropic Virus (HTLV) 1 and 2 positive versus HTLV 1 and 2 negative patients.

For CRS AE the protocol will follow the American Society of Transplant and Cellular Therapy (ASTCT) CRS Consensus Grading.

For ICANS AE the protocol will follow ASTCT consensus as well. Which establishes the Immune effector Cell-associated Encephalopathy (ICE Score) for adults/ adolescents and Cornell Assessment of Pediatric Delirium (CAPD) for pediatric patients under 12 years

Up to 15 years
Pregnancy rates
Prazo: Up to 15 years

Pregnancy rates will be collected

Up to 15 years
Number of patients with confirmed secondary malignancies diagnosis
Prazo: Up to 15 years

Number of patients with confirmed secondary malignancies diagnosis will be collected

Up to 15 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de novembro de 2023

Conclusão Primária (Estimado)

23 de novembro de 2037

Conclusão do estudo (Estimado)

23 de novembro de 2037

Datas de inscrição no estudo

Enviado pela primeira vez

13 de setembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de setembro de 2022

Primeira postagem (Real)

15 de setembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

10 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever